Accelerating Neurology OptumRx Integration for Specialty Pharmacy PAs

The Unique Demands of Neurology Pharmacy PAs with OptumRx

Neurology practices frequently manage patients requiring complex, high-cost specialty pharmacy medications for chronic conditions such as Multiple Sclerosis (MS), chronic migraine, and Alzheimer's disease. As a prominent Pharmacy Benefit Manager (PBM), OptumRx is a key gatekeeper for many of these therapies, necessitating meticulous prior authorization submissions to ensure coverage and patient access.

Key Neurology Medications Requiring OptumRx Prior Authorization

• **MS Disease-Modifying Therapies (DMTs)**: Including high-efficacy agents like ocrelizumab (Ocrevus), ofatumumab (Kesimpta), and natalizumab (Tysabri), often subject to step therapy.
• **Alzheimer's Disease Therapeutics**: Such as lecanemab (Leqembi) and donanemab (Kisunla), which demand specific documentation for amyloid confirmation and MRI screening.
• **Migraine Prevention Biologics**: CGRP monoclonal antibodies (e.g., erenumab/Aimovig, fremanezumab/Ajovy) and oral gepants that typically require prior preventive trial failures.
• **Spinal Muscular Atrophy (SMA) / ALS Treatments**: Including gene therapies like onasemnogene abeparvovec (Zolgensma) and other specialty drugs like nusinersen (Spinraza) and risdiplam (Evrysdi).
• **Botox for Chronic Migraine**: OnabotulinumtoxinA (Botox) for specific indications, requiring documentation of chronic migraine criteria and prior therapy trials.
• **Epilepsy Specialty Drugs**: Newer anti-seizure medications such as cenobamate (Xcopri) and brivaracetam (Briviact) for specific indications.

Navigating OptumRx's Specific Documentation and Step Therapy Protocols

OptumRx's prior authorization requirements for neurology drugs often align with AAN Practice Guidelines. Common challenges include stringent step therapy for MS DMTs and CGRP migraine prevention, the need for precise amyloid biomarker confirmation for Alzheimer's anti-amyloid antibodies, and detailed documentation of disease severity or prior treatment failures. Gaps in these specific requirements are frequent causes of denial.

Klivira's Automated Approach to Neurology OptumRx Integration

Klivira's platform automates the complex prior authorization workflow for neurology practices integrating with OptumRx. By leveraging ePA capabilities, including NCPDP SCRIPT for pharmacy benefits, Klivira ensures that submissions for MS DMTs, Alzheimer's therapeutics, and migraine biologics are accurate and complete. This significantly reduces manual data entry and accelerates the communication loop with OptumRx.

Streamlining EMR and Payer Touchpoints for Neurology PAs

• Automated extraction of clinical data from EMRs, including McDonald criteria for MS, headache diaries for migraine, and amyloid confirmation for Alzheimer's.
• Pre-population of OptumRx PA forms with patient demographics, diagnoses, and medication details, reducing manual effort.
• Real-time tracking of prior authorization status directly within the Klivira platform, providing transparency into OptumRx's review process.
• Proactive identification of missing documentation, ensuring all necessary clinical evidence, such as MRI findings or ApoE genotype, is included before submission.
• Management of periodic re-authorizations for chronic neurology treatments, ensuring continuous coverage.

Beyond Submission: Proactive Denial Prevention and Re-authorization

Klivira's intelligence goes beyond initial submission, incorporating AAN-guideline-aware logic to prevent common OptumRx denials related to step therapy for MS and CGRP medications. The platform tracks chronic treatment re-authorization schedules for drugs like MS DMTs, ensuring timely follow-up. This proactive management minimizes administrative burden and helps maintain continuity of care for neurology patients.